• You need to sign in or sign up before continuing.
Close
Announcements
Projects
Orgs
Project
Articles 2
Votes 0
Biogen.com
New Data from Biogen's Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer's Disease | Biogen - Biogen
~2y
FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS | Biogen - Biogen
>2y